Literature DB >> 3919058

A novel pathway for biosynthesis of cholestanol with 7 alpha-hydroxylated C27-steroids as intermediates, and its importance for the accumulation of cholestanol in cerebrotendinous xanthomatosis.

S Skrede, I Björkhem, M S Buchmann, G Hopen, O Fausa.   

Abstract

A mixture of 7 alpha-3H- and 4-14C-labeled cholesterol was administered intravenously to rats. Cholestanol with 20-30% lower ratio between 3H and 14C than in cholesterol could be isolated from different organs. In a healthy human control, cholestanol isolated from feces had a 3H/14C ratio which was 28% lower than in administered cholesterol. Cholesterol and coprostanol reisolated in these experiments had the same ratio between 3H and 14C as in the precursor. A previously unknown pathway for formation of cholestanol, involving 7 alpha-hydroxylated intermediates, may explain these results. Under normal conditions, this pathway is responsible for at most 30% of the cholestanol synthesized from cholesterol. Intravenous administration of the 7 alpha-3H- and 4-14C-labeled cholesterol to a patient with cerebrotendinous xanthomatosis (CTX) resulted in formation of cholestanol which had 70-75% lower 3H/14C ratio. It is concluded that the novel pathway involving 7 alpha-hydroxylated intermediates is accelerated in patients with CTX. This acceleration may contribute essentially to the accumulation of cholestanol, which is a predominant feature of this disease. 7 alpha-Hydroxycholesterol and 7 alpha-hydroxy-4-cholesten-3-one might be intermediates in the novel pathway to cholestanol. After intravenous administration of 7 beta-3H-labeled 7 alpha-hydroxycholesterol in a patient with CTX, significant amounts of 3H were incorporated into plasma and fecal cholestanol. Only small amounts of 7 alpha-hydroxycholesterol and 7 alpha-hydroxy-4-cholesten-3-one are excreted into the intestine, and we therefore conclude that the 7 alpha-dehydroxylation step mainly occurs in the liver. In CTX, the synthesis of cholestanol may be accelerated because the concentrations of 7 alpha-hydroxylated bile acid intermediates in the liver are increased. A possible mechanism for the conversion of a minor fraction of 7 alpha-hydroxycholesterol into cholestanol is suggested.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919058      PMCID: PMC423517          DOI: 10.1172/JCI111719

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  METABOLISM OF CHOLESTA-4,7-DIEN-3-ONE AND CHOLESTA-4,6-DIEN-3-ONE BY MOUSE LIVER MICROSOMES.

Authors:  A A KANDUTSCH
Journal:  J Lipid Res       Date:  1963-04       Impact factor: 5.922

2.  On the conversion of cholesterol to 7-alpha,12-alpha-dihydroxycholest-4-en-3-one. Bile acids and steroids 168.

Authors:  H Danielsson; K Einarsson
Journal:  J Biol Chem       Date:  1966-04-10       Impact factor: 5.157

3.  Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism.

Authors:  G Salen
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

4.  Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system.

Authors:  J H Menkes; J R Schimschock; P D Swanson
Journal:  Arch Neurol       Date:  1968-07

5.  Mechanism of microbial transformation of cholesterol into coprostanol.

Authors:  I Björkhem; J A Gustafsson
Journal:  Eur J Biochem       Date:  1971-08-16

6.  Biosynthesis of 5 -cholestan-3 -ol in cerebrotendinous xanthomatosis.

Authors:  G Salen; A Polito
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

7.  Conversion of cholesterol injected into man to cholestanol via a 3-ketonic intermediate.

Authors:  R S Rosenfeld; B Zumoff; L Hellman
Journal:  J Lipid Res       Date:  1967-01       Impact factor: 5.922

8.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.

Authors:  G Salen; S M Grundy
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  Biosynthesis of cholestanol: 5-alpha-cholestan-3-one reductase of rat liver.

Authors:  S Shefer; S Hauser; E H Mosbach
Journal:  J Lipid Res       Date:  1966-11       Impact factor: 5.922

10.  A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.

Authors:  T Setoguchi; G Salen; G S Tint; E H Mosbach
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

View more
  14 in total

1.  Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Authors:  Natalia Mast; Kyle W Anderson; Joseph B Lin; Yong Li; Illarion V Turko; Curtis Tatsuoka; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-02-11       Impact factor: 5.157

2.  Retinal and nonocular abnormalities in Cyp27a1(-/-)Cyp46a1(-/-) mice with dysfunctional metabolism of cholesterol.

Authors:  Aicha Saadane; Natalia Mast; Casey D Charvet; Saida Omarova; Wenchao Zheng; Suber S Huang; Timothy S Kern; Neal S Peachey; Irina A Pikuleva
Journal:  Am J Pathol       Date:  2014-07-25       Impact factor: 4.307

3.  Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe.

Authors:  Rgia A Othman; Semone B Myrie; David Mymin; Jean-Baptiste Roullet; Andrea E DeBarber; Robert D Steiner; Peter J H Jones
Journal:  J Pediatr       Date:  2017-06-16       Impact factor: 4.406

4.  Levels of 7alpha-hydroxycholesterol and/or 7alpha-hydroxy-4-cholest-3-one are the optimal biochemical markers for the evaluation of treatment of cerebrotendinous xanthomatosis.

Authors:  Dieter Lütjohann; Frans Stellaard; Ingemar Björkhem
Journal:  J Neurol       Date:  2019-11-28       Impact factor: 4.849

5.  Profiling sterols in cerebrotendinous xanthomatosis: utility of Girard derivatization and high resolution exact mass LC-ESI-MS(n) analysis.

Authors:  Andrea E DeBarber; Yana Sandlers; Anuradha S Pappu; Louise S Merkens; P Barton Duell; Steven R Lear; Sandra K Erickson; Robert D Steiner
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-11-23       Impact factor: 3.205

6.  On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase.

Authors:  Ann Båvner; Marjan Shafaati; Magnus Hansson; Maria Olin; Shoshi Shpitzen; Vardiella Meiner; Eran Leitersdorf; Ingemar Björkhem
Journal:  J Lipid Res       Date:  2010-05-28       Impact factor: 5.922

7.  Demonstration of 26-hydroxylation of C27-steroids in human skin fibroblasts, and a deficiency of this activity in cerebrotendinous xanthomatosis.

Authors:  S Skrede; I Björkhem; E A Kvittingen; M S Buchmann; S O Lie; C East; S Grundy
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

8.  Effects of cholestanol feeding and cholestyramine treatment on the tissue sterols in the rabbit.

Authors:  M S Buchmann; O P Clausen
Journal:  Lipids       Date:  1986-12       Impact factor: 1.880

9.  A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns.

Authors:  Andrea E DeBarber; Jenny Luo; Michal Star-Weinstock; Subhasish Purkayastha; Michael T Geraghty; John Pei-Wen Chiang; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  J Lipid Res       Date:  2013-11-02       Impact factor: 5.922

10.  Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor.

Authors:  Bryan Goodwin; Karine C Gauthier; Michihisa Umetani; Michael A Watson; Matthew I Lochansky; Jon L Collins; Eran Leitersdorf; David J Mangelsdorf; Steven A Kliewer; Joyce J Repa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.